MY186337A - Cd123 binding agents and uses thereof - Google Patents

Cd123 binding agents and uses thereof

Info

Publication number
MY186337A
MY186337A MYPI2017700741A MYPI2017700741A MY186337A MY 186337 A MY186337 A MY 186337A MY PI2017700741 A MYPI2017700741 A MY PI2017700741A MY PI2017700741 A MYPI2017700741 A MY PI2017700741A MY 186337 A MY186337 A MY 186337A
Authority
MY
Malaysia
Prior art keywords
antibodies
antigen
binding fragments
cancer
determine whether
Prior art date
Application number
MYPI2017700741A
Other languages
English (en)
Inventor
Gaudet Francois
F Nemeth Jennifer
Attar Ricardo
C Harman Benjamin
Li Yingzhe
Luo Jinquan
Mcdaid Ronan
C Pomerantz Steven
H Tam Susan
Teplyakov Alexey
Wheeler John
Wu Sheng-Jiun
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MY186337A publication Critical patent/MY186337A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
MYPI2017700741A 2014-09-05 2015-09-03 Cd123 binding agents and uses thereof MY186337A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05
PCT/US2015/048316 WO2016036937A1 (en) 2014-09-05 2015-09-03 Cd123 binding agents and uses thereof

Publications (1)

Publication Number Publication Date
MY186337A true MY186337A (en) 2021-07-13

Family

ID=54150667

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017700741A MY186337A (en) 2014-09-05 2015-09-03 Cd123 binding agents and uses thereof

Country Status (39)

Country Link
US (1) US9850310B2 (cg-RX-API-DMAC7.html)
EP (2) EP3722315A1 (cg-RX-API-DMAC7.html)
JP (2) JP6805130B2 (cg-RX-API-DMAC7.html)
KR (1) KR102540192B1 (cg-RX-API-DMAC7.html)
CN (1) CN107074956B (cg-RX-API-DMAC7.html)
AR (1) AR101765A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015311931B2 (cg-RX-API-DMAC7.html)
CA (1) CA2959171C (cg-RX-API-DMAC7.html)
CL (1) CL2017000515A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017002196A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170079A (cg-RX-API-DMAC7.html)
CY (1) CY1122858T1 (cg-RX-API-DMAC7.html)
DK (1) DK3189081T3 (cg-RX-API-DMAC7.html)
EA (1) EA037647B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17020812A (cg-RX-API-DMAC7.html)
ES (1) ES2791249T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200745T1 (cg-RX-API-DMAC7.html)
HU (1) HUE048791T2 (cg-RX-API-DMAC7.html)
IL (1) IL250770B (cg-RX-API-DMAC7.html)
JO (1) JO3568B1 (cg-RX-API-DMAC7.html)
LT (1) LT3189081T (cg-RX-API-DMAC7.html)
MA (2) MA53145A (cg-RX-API-DMAC7.html)
ME (1) ME03724B (cg-RX-API-DMAC7.html)
MX (1) MX384424B (cg-RX-API-DMAC7.html)
MY (1) MY186337A (cg-RX-API-DMAC7.html)
NI (1) NI201700025A (cg-RX-API-DMAC7.html)
PE (1) PE20171556A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500472A1 (cg-RX-API-DMAC7.html)
PL (1) PL3189081T3 (cg-RX-API-DMAC7.html)
PT (1) PT3189081T (cg-RX-API-DMAC7.html)
RS (1) RS60305B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201701599UA (cg-RX-API-DMAC7.html)
SI (1) SI3189081T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000253T1 (cg-RX-API-DMAC7.html)
TW (1) TWI693233B (cg-RX-API-DMAC7.html)
UA (1) UA120060C2 (cg-RX-API-DMAC7.html)
UY (1) UY36289A (cg-RX-API-DMAC7.html)
WO (1) WO2016036937A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201702369B (cg-RX-API-DMAC7.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2796181C (en) * 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
SI3313884T1 (sl) 2015-06-29 2021-04-30 Immunogen, Inc. Protitelesa proti CD123 ter njihovi konjugati in derivati
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
CN109641047A (zh) 2016-05-20 2019-04-16 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
RS67145B1 (sr) * 2016-05-20 2025-09-30 Harpoon Therapeutics Inc Proteini sa jednolančanim varijabilnim fragmentom koji vezuju cd3
BR112018074771A2 (pt) * 2016-06-06 2019-03-06 F. Hoffmann-La Roche Ag proteínas de fusão para oftalmologia com retenção aumentada nos olhos
US20200255524A1 (en) 2016-06-07 2020-08-13 Macrogenics, Inc. Combination therapy
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) * 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
MX2019003225A (es) * 2016-09-21 2019-06-10 Aptevo Res & Development Llc Proteínas de unión a cd123 y composiciones y métodos relacionados.
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
IL266892B2 (en) 2016-12-02 2025-10-01 Univ Southern California Artificial immune receptors and methods of using them
EP3576793A4 (en) * 2017-02-06 2021-03-31 Dana Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR INCREASING RECEPTOR SIGNALING MEDIA BY ANTIBODIES
CA3053803A1 (en) 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN121159691A (zh) 2017-05-12 2025-12-19 哈普恩治疗公司 间皮素结合蛋白质
CN110913908B (zh) 2017-05-12 2022-05-27 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
EP3668898B1 (en) 2017-08-14 2023-07-05 MorphoSys AG Humanized antibodies for cd3
US20210061911A1 (en) * 2017-09-07 2021-03-04 Macrogenics, Inc. Dosing Regiments of Bi-Specific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EA202090817A1 (ru) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. Триспецифические белки и способы их применения
IL274095B2 (en) * 2017-10-27 2025-03-01 Pfizer Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
BR112020011810A2 (pt) 2017-12-12 2020-11-17 Macrogenics, Inc. molécula de ligação cd16 x antígeno de doença, composição farmacêutica, uso da composição farmacêutica, e método para o tratamento de uma doença
EP3752196A4 (en) 2018-02-15 2022-03-23 MacroGenics, Inc. CD3-BINDING DOMAIN VARIANTS AND THEIR USE IN COMBINATION THERAPIES FOR THE TREATMENT OF DISEASES
CA3093330A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
SG11202011330PA (en) 2018-05-14 2020-12-30 Harpoon Therapeutics Inc Binding moiety for conditional activation of immunoglobulin molecules
CN120285175A (zh) 2018-05-16 2025-07-11 詹森生物科技公司 治疗癌症并增强t细胞重定向治疗剂的功效的方法
AU2019274657A1 (en) 2018-05-24 2020-12-10 Janssen Biotech, Inc. PSMA binding agents and uses thereof
US11866499B2 (en) 2018-05-24 2024-01-09 Janssen Biotech, Inc. Monospecific and multispecific anti-TMEFF2 antibodies and their uses
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
KR102306346B1 (ko) * 2018-10-17 2021-09-30 주식회사 굳티셀 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
MX2021010857A (es) * 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
KR20220017892A (ko) * 2019-05-08 2022-02-14 얀센 바이오테크 인코포레이티드 T세포 매개 면역의 조절을 위한 물질 및 방법
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
CN113912695B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白及应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
KR20220144821A (ko) 2020-02-21 2022-10-27 마크로제닉스, 인크. Cd137 결합 분자 및 그것의 용도
UY40280A (es) 2020-03-13 2023-07-31 Janssen Biotech Inc Dominios de unión a antígeno que se unen a la proteina cd33 de la superficie de células mieloides
JP7770339B2 (ja) 2020-05-19 2025-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫応答を誘導するためのコンジュゲートポリペプチドおよびワクチン
MX2022014426A (es) * 2020-05-19 2023-04-21 Janssen Biotech Inc Composiciones que comprenden una terapéutica de redirección de células t y un inhibidor de la ruta de adhesión de vla-4.
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
MX2023004598A (es) * 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
JP7623497B2 (ja) 2020-12-31 2025-01-28 サノフイ ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ
KR20230157315A (ko) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 치료하기 위한 조성물 및 방법
AU2022278013A1 (en) 2021-05-18 2024-01-18 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
GB2638094A (en) 2021-05-19 2025-08-13 Asher Biotherapeutics Inc Il-21 Polypeptides And Targeted Constructs
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
US20250144213A1 (en) * 2022-01-19 2025-05-08 Utc Therapeutics (Shanghai) Co., Ltd. Circular rna and use thereof
IL316002A (en) 2022-04-11 2024-11-01 Regeneron Pharma Compositions and methods for universal tumor cell killing
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物
EP4665385A2 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1997024373A1 (en) 1995-12-29 1997-07-10 Medvet Science Pty. Limited Monoclonal antibody antagonists to haemopoietic growth factors
AU9393398A (en) 1997-09-16 1999-04-05 Egea Biosciences, Inc. Method for the complete chemical synthesis and assembly of genes and genomes
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20060204493A1 (en) 2004-09-02 2006-09-14 Genentech, Inc. Heteromultimeric molecules
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
AU2010242598C1 (en) * 2009-04-27 2015-02-05 Kyowa Kirin Co., Ltd. Anti-IL-3Ralpha antibody for use in treatment of blood tumor
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011038301A2 (en) * 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
EP2850106B1 (en) * 2012-05-18 2022-03-23 Aptevo Research and Development LLC Bispecific scfv immunofusion (bif) binding to cd123 and cd3

Also Published As

Publication number Publication date
EA037647B1 (ru) 2021-04-27
KR20170049554A (ko) 2017-05-10
PT3189081T (pt) 2020-05-25
SMT202000253T1 (it) 2020-07-08
CN107074956B (zh) 2021-11-26
ME03724B (me) 2021-01-20
MA40609B1 (fr) 2020-05-29
JP2017529838A (ja) 2017-10-12
CA2959171A1 (en) 2016-03-10
CN107074956A (zh) 2017-08-18
WO2016036937A1 (en) 2016-03-10
DK3189081T3 (da) 2020-05-04
JP2021050216A (ja) 2021-04-01
PL3189081T3 (pl) 2020-10-05
AU2015311931A1 (en) 2017-03-16
MA53145A (fr) 2021-05-19
BR112017004322A2 (pt) 2017-12-05
CL2017000515A1 (es) 2018-03-16
EP3722315A1 (en) 2020-10-14
SG11201701599UA (en) 2017-03-30
JO3568B1 (ar) 2020-07-05
SI3189081T1 (sl) 2020-07-31
AU2015311931B2 (en) 2020-09-03
IL250770A0 (en) 2017-04-30
PH12017500472A1 (en) 2017-07-31
US9850310B2 (en) 2017-12-26
KR102540192B1 (ko) 2023-06-02
EA201790530A1 (ru) 2018-03-30
HRP20200745T1 (hr) 2020-08-07
CR20170079A (es) 2017-04-27
CA2959171C (en) 2023-11-14
PE20171556A1 (es) 2017-10-27
EP3189081A1 (en) 2017-07-12
CO2017002196A2 (es) 2017-07-28
AR101765A1 (es) 2017-01-11
NI201700025A (es) 2017-06-22
EP3189081B1 (en) 2020-02-19
MX384424B (es) 2025-03-14
UY36289A (es) 2016-04-01
TW201625687A (zh) 2016-07-16
US20160068605A1 (en) 2016-03-10
ZA201702369B (en) 2018-12-19
MX2017002891A (es) 2017-10-11
CY1122858T1 (el) 2021-05-05
ES2791249T3 (es) 2020-11-03
LT3189081T (lt) 2020-05-11
IL250770B (en) 2020-10-29
TWI693233B (zh) 2020-05-11
UA120060C2 (uk) 2019-09-25
HUE048791T2 (hu) 2020-09-28
RS60305B1 (sr) 2020-07-31
JP6805130B2 (ja) 2020-12-23
ECSP17020812A (es) 2018-07-31

Similar Documents

Publication Publication Date Title
PH12017500472A1 (en) Cd123 binding agents and uses thereof
MX2022006650A (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos.
PH12019500152A1 (en) Anti-gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
PH12018500938A1 (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind ili1rap and cd3, and uses thereof